EQS Group-News: Zur Rose Group AG
/ Key word(s): Miscellaneous
23.03.2020 / 11:00
Frauenfeld, 23 March 2020
COVID-19: Zur Rose is calling for an exception allowing the mail-orders for over-the-counter emergency, cold and flu medicines
The coronavirus is having a huge impact on public life and curtailing freedom of movement. In these circumstances, the mail-order business is becoming ever more important. In Switzerland, however, non-prescription medicines can only be delivered by mail when specifically allowed by a doctor. Zur Rose is therefore calling for an exemption to be granted, temporarily allowing non-prescription emergency, cold and flu medicines (over-the-counter medicines) to be sold by mail order. Online pharmacies can play an effective role in protecting the population right now, helping to curb the spread of the coronavirus and taking some of the pressure off bricks-and-mortar pharmacies and their exposed staff.
In COVID-19 Directive 2, the Federal Council outlines measures for reducing the risk of transmission and for combating the coronavirus. The next few weeks will show whether the regulations and our behaviour as a society can help slow down the rapid spread of the virus we are currently witnessing in Switzerland. It is vital to ensure that Switzerland is able to supply its population with medicines and at the same time avoid any further spread of the virus. What people who are in quarantine and who are at risk need right now are simple, quick and reliable supplies, and online pharmacies such as Zur Rose can step in here.
Improve protection for everyone – by allowing mail orders for OTC medicines
Highest safety standards – supporting the Federal Council’s restrictions
Pascale Ineichen, Corporate Communications Zur Rose Suisse AG
Zur Rose Suisse AG
Zur Rose Suisse AG, a subsidiary of Zur Rose Group AG, is one of Switzerland’s leading mail-order pharmacies and medical wholesalers. With its business model, it offers high-quality, safe and cost-effective pharmaceutical care and thus contributes to reducing healthcare costs. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose Group is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform – the Zur Rose ecosystem – it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions. For further information please see zurrose.ch and zurrosegroup.com.
End of Corporate News
|Company:||Zur Rose Group AG|
|Phone:||+41 52 724 08 14|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1003977|
|End of News||EQS Group News Service|